NOU 2012: 17

Om kjærlighet og kjøletårn

1.15 Avslutning

Selv om HIV/AIDS-epidemien synes å ha kulminert globalt, er det en stadig dynamikk i spredningen av HIV-viruset som gjør at det regionale bildet vil kunne gjennomgå store endringer i årene fremover. Epidemien har allerede skapt store problemer i en rekke land, i særlig grad i flere land i sub-Sahara Afrika. Fortsatt gjenstår store medisinske utfordringer både når det gjelder forebyggelse og behandling. Forskningsinnsatsen på HIV/AIDS-feltet er imidlertid massiv, særlig i vestlige land.

Det gir imidlertid grunn til bekymring at den farmasøytiske industri internasjonalt, etter å ha satset sterkt i en årrekke på utvikling av de antiretrovirale medikamenter vi benytter i dag, nå synes å trappe ned sin innsats når det gjelder utvikling av helt nye HIV-medikamenter. Hvis man i årene fremover får en betydelig økning av HIV-pasienter med virus som er resistent over for alle de anvendte medikamentgrupper i dag, vil man derfor kunne få en ny, alvorlig epidemisk utvikling.

Referanser

  1. Centers for disease control (CDC). Kaposi's sarcoma and pneumocystis pneumonia in homosexual men in California. MMWR Morb Mortal Weekly Rep 1981;30:305-8.

  2. Centers for disease control and prevention. Update on acquired immune deficiency syndrome (AIDS) in United States. MMWR Morb Mortal Weekly Rep 1982;31:507-14.

  3. Frøland SS, Oppedal B, Digranes S, Egge K, Skar AG, Hasvoll A, Onsrud M, Steinbakk M. Acquired immunodeficiency syndrome (AIDS). Clinical, immunological, pathological, and microbiological studies of the first case diagnosed in Norway. Scand J Gastroenterol suppl. 1985;20:82-93.

  4. Hahn BH, Shaw GM, Arya SK, Popovic M, Gallo RC, Wong-Staal F. Molecular cloning and characterization of the HTLV-III virus associated with AIDS. Nature 1984;312:166-69.

  5. Alizon M, Sonigo P, Barré-Sinoussi F, Chermann JC, Tiollais P, Montagnier L, Wain-Hobson S. Molecular cloning of lymphadenopathy-associated virus. Nature. 1984;312:757-60.

  6. Daskalakis D. HIV diagnostic testing: evolving technology and testing strategies. Top Antivir Med. 2011;19:18-22.

  7. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984;312:763-7.

  8. Fischl M.A., Richman D.D., Grieco M.H., et al. The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex. N Engl J Med 1987; 317:185-191.

  9. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, VanDyke R, Bey M, Shearer W, Jacobson RL, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994 Nov 3;331(18):1173-80.

  10. Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med. 1996;335:1081-90.

  11. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-60.

  12. Vermund SH. Millions of life-years saved with potent antiretroviral drugs in the United States: a celebration, with challenges. J Infect Dis. 2006;194:1-5.

  13. Tebit DM, Arts EJ. Tracking a century of global expansion and evolution of HIV to drive understanding and to combat disease. Review Article. The Lancet Infectious Diseases, 2011;11: 45-56.

  14. M-C Boily, RF Baggaley, L Wang, B Masse, RG White, RJ Hayes, M Alary. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. The Lancet Infectious Diseases, 2009;9:118-129.

  15. Dosekun O, Fox J. An overview of the relative risks of different sexual behaviours on HIV transmission. Curr Opin HIV AIDS. 2010l;5:291-7.

  16. Fox J, Fidler S. Sexual transmission of HIV-1. Antiviral Research, 2010;85:276-285.

  17. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber C-M, Saragosti S, Lapouméroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtonboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene 722. Nature 1996;382:722-25. doi:10.1038/382722a0.

  18. Eugen-Olsen J, Iversen AK, Garred P, Koppelhus U, Pedersen C, Benfield TL, Sorensen AM, Katzenstein T, Dickmeiss E, Gerstoft J, Skinhøj P, Svejgaard A, Nielsen JO, Hofmann B. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS. 1997;11:305-10.

  19. Cohen MS. Classical Sexually Transmitted Diseases Drive the Spread of HIV-1: Back to the Future. J Infect Dis. 2012;206:1-2.

  20. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, Meehan MO, Lutalo T, Gray RH. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921-9.

  21. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, Kiwanuka N, Kigozi G, Kiddugavu M, Lutalo T, Nalugoda F, Wabwire-Mangen F, Meehan MP, Quinn TC. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191:1403-9.

  22. Baggaley RF, White RG, Boily MC. Systematic review of orogenital HIV-1 transmission probabilities. Int J Epidemiol. 2008;37:1255-65.

  23. Busch MP, Young MJ, Samson SM, Mosley JW, Ward JW, Perkins HA. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. The Transfusion Safety Study Group. Transfusion. 1991;31:4-11.

  24. Evensen SA, Ulstrup J, Skaug K, Frøland SS, Glomstein A, Rollag H. HIV infection in Norwegian haemophiliacs: the prevalence of antibodies against HIV in haemophiliacs treated with lyophilized cryoprecipitate from volunteer donors. Eur J Haematol. 1987;39:44-8.

  25. Grant RM. Antiretroviral Agents Used by HIV-Uninfected Persons for Prevention: Pre- and Postexposure Prophylaxis. Clin Infect Dis. 2010;50(Suppl 3): S96-S101.

  26. Stimson GV. The global diffusion of injecting drug use: implications for human immunodeficiency virus infection. Bull Narc. 1993;45:3-17.

  27. European Collaborative Study. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS 2001;15:761-770.

  28. Redd AD, Mullis CE, Serwadda D, Kong X, Martens C, Ricklefs SM, Tobian AA, Xiao C, Grabowski MK, Nalugoda F, Kigozi G, Laeyendecker O, Kagaayi J, Sewankambo N, Gray RH, Porcella SF, Wawer MJ, Quinn TC. The Rates of HIV Superinfection and Primary HIV Incidence in a General Population in Rakai, Uganda. J Infect Dis. 2012;206:267-74.

  29. Waters L, Smit E. HIV-1 superinfection. Curr Opin Infect Dis. 2012;25:42-50.

  30. UNAIDS report on the global AIDS epidemic, 2010. http://www.unaids.org/globalreport/

  31. Thorne C, Ferencic N, Malyuta R, Mimica J, Niemiec T. Central Asia: hotspot in the worldwide HIV epidemic. Lancet Infect Dis. 2010;10:479-88.

  32. Matic S, Lazarus JV, Donoghoe C (red.). HIV/AIDS in Europe. Moving from death sentence to chronic disease management. WHO 2006.

  33. Folkehelseinstituttet. HIV-situasjonen i Norge i 2011. Publisert 2.3.2012, oppdatert 9.3.2012.

  34. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010;464:217-23.

  35. Moir S, Chun T-W, Fauci AS. Pathogenic Mechanisms of HIV Disease. Ann Rev pathology 2010; 6: 23–248.

  36. Ford ES, Puronen CE, Sereti I. Immunopathogenesis of asymptomatic chronic HIV Infection: the calm before the storm. Curr Opin HIV AIDS. 2009;4:206-14.

  37. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.

  38. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993;262:1011-1018.

  39. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol. 2008;214:231-41.

  40. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, Kuller LH, Pett SL, Ristola M, Ross MJ, Shlipak MG, Tracy R, Neaton JD. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201:1788-95.

  41. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009;338:288-92.

  42. Blanco JR, Caro AM, Pérez-Cachafeiro S, Gutiérrez F, Iribarren JA, González-García J, Ferrando-Martínez S, Navarro G, Moreno S. HIV infection and aging. AIDS Rev. 2010;12:218-30.

  43. Dubé MP, Sattler FR. Inflammation and complications of HIV disease. J Infect Dis. 2010;201:1783-5.

  44. Tindall B, Barker S, Donovan B, Barnes T, Roberts J, Kronenberg C, Gold J, Penny R, Cooper D. Characterization of the acute clinical illness associated with human immunodeficiency virus infection. Arch Intern Med. 1988;148:945-9.

  45. Lifson AR, Rutherford GW, Jaffe HW. The natural history of human immunodeficiency virus infection. J Infect Dis. 1988 ;158:1360-7.

  46. Rutherford GW, Lifson AR, Hessol NA, Darrow WW, O'Malley PM, Buchbinder SP, Barnhart JL, Bodecker TW, Cannon L, Doll LS, et al. Course of HIV-I infection in a cohort of homosexual and bisexual men: an 11 year follow up study. BMJ. 1990;301:1183-8.

  47. Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR Jr. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-54.

  48. Laga M, Nzila N, Goeman J. The interrelationship of sexually transmitted diseases and HIV infection: implications for the control of both epidemics in Africa. AIDS 1991;5; Suppl 1:S55-63.

  49. Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev. 2001;14:753-77.

  50. Spencer DC, Price RW. Human immunodeficiency virus and the central nervous system. Annu Rev Microbiol. 1992;46:655-93.

  51. Plaeger SF, Collins BS, Musib R, Deeks SG, Read S, Embry A. Immune Activation in the Pathogenesis of Treated Chronic HIV Disease: A Workshop Summary. AIDS Res Hum Retroviruses. 2012;28:469-77.

  52. Frøland SS. 25 years of the AIDS epidemic. Tidsskr Nor Legeforen. 2006;126:3140-4.

  53. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010;376:49-62.

  54. European AIDS Clinical Society, EACS. Guidelines. Version 6.1 – november 2011. www.europeanaidsclinicalsociety.org

  55. Cohen MS, Chen YQ, McCauley M, Gamble T, et al. HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.

  56. Walker AS, Gibb DM. Monitoring of highly active antiretroviral therapy in HIV infection. Curr Opin Infect Dis. 2011;24:27-33.

  57. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, Montaner JS. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450-4.

  58. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sørensen HT, Vaeth M, Obel N. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007;146:87-95.

  59. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. The Lancet 2008;372:293–299

  60. May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, Dunn D, Palfreeman A, Gilson R, Gazzard B, Hill T, Walsh J, Fisher M, Orkin C, Ainsworth J, Bansi L, Phillips A, Leen C, Nelson M, Anderson J, Sabin C. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ. 2011;343:d6016. doi: 10.1136/bmj.d6016

  61. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356:1423-30.

  62. Wit FW, Weverling GJ, Jurriaans S, Lange JMA. Incidence of and Risk Factors for Severe Hepatotoxicity Associated with Antiretroviral Combination Therapy. J Infect Dis. 2002;186:23-31. doi:10.1086/341084

  63. Pham PA, Flexner C. Emerging antiretroviral drug interactions. J Antimicrob Chemother. 2011;66:235-9.

  64. Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, Bertisch B, Bernasconi E, Weber R; Swiss HIV Cohort Study. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011 Dec;53(11):1130-9.

  65. Zhao H, Goetz MB. Complications of HIV infection in an ageing population: challenges in managing older patients on long-term combination antiretroviral therapy. J. Antimicrob. Chemother. 2011;66:1210-14. doi:10.1093/jac/dkr058

  66. Clavel F, Hance AJ. Medical Progress: HIV Drug Resistance. New Eng J Med 2004;350:1023-35.

  67. Reynolds SJ, Quinn TC. Setting the stage: current state of affairs and major challenges. Clin Infect Dis. 2010;50: Suppl 3:S71-S76.

  68. Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009;23:1397-404.

  69. Vernazza P, Hirschel B, Bernasconi E, Flepp M. Les personnes séropositives ne souffrant d'aucune autre MST et suivant un traitement antiretroviral efficace ne transmettent pas le VIH par voie sexuelle. Bull Med Suisse 208;89:165-69.

  70. Wilson DP. Data are lacking for quantifying HIV transmission risk in the presence of effective antiretroviral therapy. AIDS. 2009;23:1431-3.

  71. Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM. Relation between HIV viral load and infectiousness: a model-based analysis Original Research Article. The Lancet, 2008;372:314-320(Erratum in: Lancet. 2008;372:1808.)

  72. De Cock KM, Gilks CF, Lo YR, Guerma T. Can antiretroviral therapy eliminate HIV transmission? Lancet. 2009;373:7-9.

  73. Centers for Disease Control and Prevention. CDC underscores current recommendation for preventing HIV transmission. 1 february 2008, http://www.cdc.gov/hiv/resources/press/020108.htm

  74. Public Health Agency of Canada. PHAC continues to emphasize safer sex for preventing HIV transmission. 17 april 2008 (http://www.phac-aspc.gc.ca/aids-sida/new-nouv-eng.php

  75. Anglemyer A, Rutherford GW, Baggaley RC, Egger M, Siegfried N. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev. 2011;CD009153.

  76. Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Horne FM, Huebner RE, Janoff EN, Justice AC, Kuritzkes D, Nayfield SG, Plaeger SF, Schmader KE, Ashworth JR, Campanelli C, Clayton CP, Rada B, Woolard NF, High KP. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis. 2008;47:542-53.

  77. Capeau J. Premature Aging and Premature Age-Related Comorbidities in HIV-Infected Patients: Facts and Hypotheses. Clin Infect Dis. 2011;53:1127-9.

  78. Martin J, Volberding P. HIV and Premature Aging: A Field Still in Its Infancy. Ann Intern Med 2010 ;153:477-79.

  79. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, Berti A, Rossi E, Roverato A, Palella F. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120-6.

  80. Lo J, Plutzky J. The biology of atherosclerosis: general paradigms and distinct pathogenic mechanisms among HIV-infected patients. J Infect Dis. 2012;205;Suppl 3:S368-74.

  81. McArthur J C, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: Mind the gap. Ann Neurol 2010;67:699-714.

  82. Mothobi NZ, Brew BJ. Neurocognitive dysfunction in the highly active antiretroviral therapy era. Curr Opin Infect Dis. 2012;25:4-9.

  83. Harezlak J, Buchthal S, Taylor M, Schifitto G, Zhong J, Daar E, Alger J, Singer E, Campbell T, Yiannoutsos C, Cohen R, Navia B; HIV Neuroimaging Consortium. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS 2011;25:625-33.

  84. Gilling-Smith C, Nicopoullos JD, Semprini AE, Frodsham LC. HIV and reproductive care--a review of current practice. BJOG. 2006;113:869-78.

  85. Van Leeuwen E, Repping S, Prins JM, Reiss P, van der Veen F. Assisted reproductive technologies to establish pregnancies in couples with an HIV-1-infected man. The Netherlands Journal of Medicine 2009;87:322-27.

  86. Martin F, Taylor GP. The safety of highly active antiretroviral therapy for the hiv-positive pregnant mother and her baby: is «the more the merrier»? J Antimicrobial Chemotherapy 2009;64:895-900.

  87. Watts DH, Huang S, Culnane M, Kaiser KA, Scheuerle A, Mofenson L, Stanley K, Newell ML, Mandelbrot L, Delfraissy JF, Cunningham CK. Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. J Perinat Med. 2011;39:163-70.

  88. Kenny J, Musiime V, Judd A, Gibb D. Recent advances in pharmacovigilance of antiretroviral therapy in HIV-infected and exposed children. Curr Opin HIV AIDS. 2012;7:305-16.

  89. Abecasis AB, Geretti AM, Albert J, Power L, Weait M, Vandamme AM. Science in court: the myth of HIV fingerprinting. Lancet Infect Dis. 2011;11:78-9.

  90. Leitner T. Guidelines for HIV in court cases. Nature. 2011;473:284.

  91. Anderson BL, Cu-Uvin S. Pregnancy and optimal care of HIV-infected patients. HIV/AIDS 2009;48:449-55.

  92. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2001;(3):CD003255. Update in: Cochrane Database Syst Rev. 2002;(1):CD003255.

  93. Romanelli F, Murphy B. Systemic preexposure prophylaxis for human immunodeficiency virus infection. Pharmacotherapy. 2010;30:1021-30.

  94. Pirrone V, Thakkar N, Jacobson JM, Wigdahl B, Krebs FC. Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob Agents Chemother. 2011;55:1831-42.

  95. Dieffenbach CW, Fauci AS. Universal Voluntary Testing and Treatment for Prevention of HIV Transmission. JAMA 2009;301:2380-2382. doi:10.1001/jama.2009.828.

  96. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48-57.

  97. Wilson DP. HIV treatment as prevention: natural experiments highlight limit of antiretroviral treatment as HIV prevention. PLoS Med 2012 July: e1001231 doi:10.1371/journal pmed 10012391

  98. Cohen MS, Muessig KE, Smith MK, Powers K, Kashuba AD. Antiviral agents and HIV prevention: controversies, conflicts and consensus. AIDS. 2012 Apr 12, ahead of print.

  99. McKinnon LR, Card CM. HIV Vaccine Efficacy Trials: A Brief History, and Options for Going Forward. AIDS Rev 2010;12:209-17.

  100. Picker LJ, Hansen SG, Lifson JD. New paradigms for HIV/AIDS vaccine development. Annu Rev Med. 2012;63:95-111.

  101. García F. 'Functional cure' of HIV infection: the role of immunotherapy. Immunotherapy. 2012;4:245-8.

  102. Hsue PY, Deeks SG, Hunt PW. Immunologic basis of cardiovascular disease in HIV-infected adults. J Infect Dis. 2012;205; Suppl 3:S375-82.

  103. Frøland SS. Gene therapy in HIV infection and other viral infections. Tidsskr Nor Legeforen. 2001;121:473-8.

  104. Seclén E. Hot News Gene Therapy Towards HIV Cure. AIDS Rev 2011;13:130-1.

  105. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997;387:183-8.

  106. Le Douce V, Janossy A, Hallay H, Ali S, Riclet R, Rohr O, Schwartz C. Achieving a cure for HIV infection: do we have reasons to be optimistic? J Antimicrob Chemother. 2012;67:1063-74.